Show simple item record

dc.contributor.authorGagliardi, T
dc.contributor.authorAdejolu, M
dc.contributor.authordeSouza, NM
dc.date.accessioned2022-05-27T09:21:20Z
dc.date.available2022-05-27T09:21:20Z
dc.date.issued2022-03-10
dc.identifier.citationJournal of clinical medicine, 2022, 11 (6), pp. 1524 - ?en
dc.identifier.issn2077-0383
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/5151
dc.identifier.eissn2077-0383en_US
dc.identifier.eissn2077-0383
dc.identifier.doi10.3390/jcm11061524en_US
dc.identifier.doi10.3390/jcm11061524
dc.description.abstractDetection, characterization, staging, and response assessment are key steps in the imaging pathway of ovarian cancer. The most common type, high grade serous ovarian cancer, often presents late, so that accurate disease staging and response assessment are required through imaging in order to improve patient management. Currently, computerized tomography (CT) is the most common method for these tasks, but due to its poor soft-tissue contrast, it is unable to quantify early response within lesions before shrinkage is observed by size criteria. Therefore, quantifiable techniques, such as diffusion-weighted magnetic resonance imaging (DW-MRI), which generates high contrast between tumor and healthy tissue, are increasingly being explored. This article discusses the basis of diffusion-weighted contrast and the technical issues that must be addressed in order to achieve optimal implementation and robust quantifiable diffusion-weighted metrics in the abdomen and pelvis. The role of DW-MRI in characterizing adnexal masses in order to distinguish benign from malignant disease, and to differentiate borderline from frankly invasive malignancy is discussed, emphasizing the importance of morphological imaging over diffusion-weighted metrics in this regard. Its key role in disease staging and predicting resectability in comparison to CT is addressed, including its valuable use as a biomarker for following response within individual lesions, where early changes in the apparent diffusion coefficient in peritoneal metastases may be detected. Finally, the task of implementing DW-MRI into clinical trials in order to validate this biomarker for clinical use are discussed, along with the trials that include it within their protocols.en_US
dc.formatElectronicen_US
dc.format.extent1524 - ?en_US
dc.languageengen_US
dc.language.isoengen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleDiffusion-Weighted Magnetic Resonance Imaging in Ovarian Cancer: Exploiting Strengths and Understanding Limitations.en
dc.typeJournal Article
dcterms.dateAccepted2022-03-08
rioxxterms.versionVoRen
rioxxterms.versionofrecord10.3390/jcm11061524en
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0en
rioxxterms.licenseref.startdate2022-03-10
dc.relation.isPartOfJournal of clinical medicineen_US
pubs.issue6en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Magnetic Resonance
pubs.publication-statusPublisheden_US
pubs.volume11en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMagnetic Resonance
dc.contributor.icrauthordeSouza, Nanditaen_US


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/